Bayer and the US biopharmaceutical company Arvinas have entered into a partnership regarding the use of Arvinas’ Proteolysis-Targeting Chimera (PROTAC) technology, coupled with Bayer’s expertise in health and agriculture, to develop innovations in both the health and agriculture sectors. PROTAC harnesses the natural protein degradation system of the cell to selectively remove target proteins by proteolysis – the breakdown of proteins into amino acids. As part of this partnership, Bayer and Arvinas will form an exclusive joint venture exploring the use of PROTAC technology in agriculture for crop protection. Bayer has committed over $55 million over a six-year period to develop an agro-specific PROTAC IP portfolio.